These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 34097287)

  • 1. Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.
    Sheikh O; Yokota T
    BioDrugs; 2021 Jul; 35(4):389-399. PubMed ID: 34097287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
    Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
    Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
    Abreu NJ; Waldrop MA
    Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.
    Dzierlega K; Yokota T
    Gene Ther; 2020 Sep; 27(9):407-416. PubMed ID: 32483212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.
    Vita G; Vita GL; Musumeci O; Rodolico C; Messina S
    Neurol Sci; 2019 Apr; 40(4):671-681. PubMed ID: 30805745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy.
    López-Martínez A; Soblechero-Martín P; Arechavala-Gomeza V
    Methods Mol Biol; 2022; 2434():217-233. PubMed ID: 35213020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
    Sheikh O; Yokota T
    Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
    Hwang J; Yokota T
    Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing therapy for neuromuscular disease.
    Douglas AG; Wood MJ
    Mol Cell Neurosci; 2013 Sep; 56():169-85. PubMed ID: 23631896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach.
    Patterson G; Conner H; Groneman M; Blavo C; Parmar MS
    Eur J Pharmacol; 2023 May; 947():175675. PubMed ID: 36963652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
    Czifrus E; Berlau DJ
    Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.